Results 331 to 340 of about 843,121 (388)

Plasma Metabolic Profile with Machine Learning Reveals Distinct Diagnostic and Biological Signatures for Pathologic Myopia

open access: yesAdvanced Science, EarlyView.
Plasma metabolic detection combined with machine learning offers a precise (area under the curve of 0.874) and high‐throughput (<30 s) diagnosis for pathologic myopia (serious myopic macular degeneration). The biomarkers indicate the pathologic myopia‐associated systemic metabolic reprogramming, which exhibits specificity for myopic macular ...
Ziheng Qi   +13 more
wiley   +1 more source

eIF4E Enriched Extracellular Vesicles Induce Immunosuppressive Macrophages through HMGCR‐Mediated Metabolic Rewiring

open access: yesAdvanced Science, EarlyView.
Here, it is revealed that ovarian cancer cells release extracellular vesicles enriched with eIF4E, which alters protein production in macrophages. This leads to increased expression of 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase (HMGCR), boosting cholesterol synthesis and activating an immunosuppressive pathway through X‐box binding protein 1 and ...
Sonam Mittal   +15 more
wiley   +1 more source

Painting Peptides With Antimicrobial Potency Through Deep Reinforcement Learning

open access: yesAdvanced Science, EarlyView.
AMPainter is a powerful design model for ’painting’ the antimicrobial potency on any given peptide sequence, based on the strategy of virtual directed evolution and deep reinforcement learning. Abstract In the post‐antibiotic era, antimicrobial peptides (AMPs) are considered ideal drug candidates because of their lower likelihood of inducing resistance.
Ruihan Dong, Qiushi Cao, Chen Song
wiley   +1 more source

AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists

open access: yesAdvanced Science, EarlyView.
De novo GLP‐1RAs can be computationally designed to exhibit extended half‐life and superior efficacy compared to Semaglutide. Abstract Peptide drugs have revolutionized modern therapeutics, offering novel treatment avenues for various diseases. Nevertheless, low design efficacy, time consumption, and high cost still hinder peptide drug design and ...
Ting Wei   +13 more
wiley   +1 more source

KLK1 as an Epithelial‐Specific Brake Inhibits Colorectal Tumorigenesis by Suppressing B1R‐Mediated Fibroblast Phenotypic Transition

open access: yesAdvanced Science, EarlyView.
KLK1 downregulation disrupts the intestinal mucosal barrier and impairs kallikrein‐kinin signaling, thereby reducing Lys‐des‐Arg9‐BK production. This enhances B1R activation on ADAMDEC1⁺ fibroblasts, promoting inflammation and extracellular matrix (ECM) remodeling. The resulting iCAFs promote colorectal cancer progression, highlighting a novel KLK1‐B1R
Lisha Zhou   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy